Literature DB >> 30799804

The Promising Signatures of Circulating microRNA-145 in Epithelial Ovarian Cancer Patients.

Mariyam Zuberi1, Rashid Mir2, Imran Khan3, Jamsheed Javid2, Sameer Ahmad Guru1, Musadiq Bhat1, Mamta Pervin Sumi1, Imtiyaz Ahmad1, Mirza Masroor1, Prasant Yadav1, Sreenivas Vishnubhatla4, Alpana Saxena1.   

Abstract

BACKGROUND: Epithelial ovarian cancer continues to be a deleterious threat to women as it is asymptomatic and is typically detected in advanced stages. Cogent non-invasive biomarkers are therefore needed which are effective in apprehending the disease in early stages. Recently, miRNA deregulation has shown a promising magnitude in ovarian cancer tumorigenesis. miRNA-145(miR- 145) is beginning to be understood for its possible role in cancer development and progression. In this study, we identified the clinicopathological hallmarks altered owing to the downexpression of serum miR-145 in EOC.
METHODS: 70 serum samples from histopathologically confirmed EOC patients and 70 controls were collected. Total RNA from serum was isolated by Trizol method, polyadenylated and reverse transcribed into cDNA. Expression level of miR-145 was detected by miRNA qRT-PCR using RNU6B snRNA as reference.
RESULTS: The alliance of miR-145 profiling amongst patients and controls established itself to be conspicuous with a significant p-value (p<0.0001). A positive conglomeration (p=0.04) of miR-145 profiling was manifested with histopathological grade. Receiver Operating Characteristic (ROC) curve highlights the diagnostic potential and makes it imminent with a robust Area Under the curve (AUC). A positive correlation with the ROC curve was also noted for histological grade, FIGO stage, distant metastasis, lymph node status and survival.
CONCLUSION: Our results propose that miR-145 down-regulation might be a possible touchstone for disease progression and be identified as a diagnostic marker and predict disease outcome in EOC patients. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Circulating miRNAs; ROC; clinicopathological; diagnosis; non-invasive; prognosis.

Mesh:

Substances:

Year:  2020        PMID: 30799804     DOI: 10.2174/2211536608666190225111234

Source DB:  PubMed          Journal:  Microrna


  9 in total

1.  The potential value of microRNA-145 for predicting prognosis in patients with ovarian cancer: A protocol for systematic review and meta-analysis.

Authors:  Zhen Chen; Zelan Xiao; Siheng Zeng; Zhiqiang Yan
Journal:  Medicine (Baltimore)       Date:  2021-08-13       Impact factor: 1.817

2.  Identification of Stably Expressed Reference microRNAs in Epithelial Ovarian Cancer.

Authors:  Joanna Lopacinska-Joergensen; Douglas V N P Oliveira; Claus K Hoegdall; Estrid V Hoegdall
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

3.  The Accuracy of Single MicroRNAs in Peripheral Blood to Diagnose Ovarian Cancer: An Updated Meta-Analysis.

Authors:  Yubao Cui; Shanchao Hong; Xuming Zhu
Journal:  Dis Markers       Date:  2020-01-14       Impact factor: 3.434

4.  Clinical Value and Potential Mechanism of miRNA-33a-5p in Lung Squamous Cell Carcinoma.

Authors:  Xiang-Ming Wang; Shang-Wei Chen; Gang Chen; Hua-Fu Zhou; Ting-Qing Gan; Jing-Jing Zeng; Zu-Yun Li
Journal:  Anal Cell Pathol (Amst)       Date:  2021-11-29       Impact factor: 2.916

Review 5.  Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations.

Authors:  Stanislas Quesada; Michel Fabbro; Jérôme Solassol
Journal:  Cancers (Basel)       Date:  2022-02-23       Impact factor: 6.639

Review 6.  Circulating non-coding RNAs in recurrent and metastatic ovarian cancer.

Authors:  Heidi Schwarzenbach; Peter B Gahan
Journal:  Cancer Drug Resist       Date:  2019-09-19

Review 7.  Extracellular vesicle contents as non-invasive biomarkers in ovarian malignancies.

Authors:  Lindsey A McAlarnen; Prachi Gupta; Reena Singh; Sunila Pradeep; Pradeep Chaluvally-Raghavan
Journal:  Mol Ther Oncolytics       Date:  2022-08-05       Impact factor: 6.311

8.  MiRNA expression deregulation correlates with the Oncotype DX® DCIS score.

Authors:  Olivier Loudig; Megan I Mitchell; Iddo Z Ben-Dov; Christina Liu; Susan Fineberg
Journal:  Breast Cancer Res       Date:  2022-09-12       Impact factor: 8.408

9.  LncRNA MALAT1 Promotes Survival of Epithelial Ovarian Cancer Cells by Downregulating miR-145-5p.

Authors:  Ye Zhao; Yi-Min Wang; Ke Wang
Journal:  Cancer Manag Res       Date:  2020-11-06       Impact factor: 3.989

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.